TY - JOUR
T1 - Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
AU - van Herwaarden, Noortje
AU - Den Broeder, Alfons
AU - Jacobs, Wilco
AU - Bijlsma, Johannes W.J.
AU - Van Vollenhoven, Ronald F.
AU - Van den Bemt, Bart J.F.
PY - 2013/4/30
Y1 - 2013/4/30
N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the benefits and harms on disease activity, functioning, costs, safety and radiographic damage of down titration (dose reduction, interval increase or discontinuation) of tumor necrosis factor blocking (anti-TNF) agents (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) compared with usual care in patients with rheumatoid arthritis (RA) and low disease activity.
AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the benefits and harms on disease activity, functioning, costs, safety and radiographic damage of down titration (dose reduction, interval increase or discontinuation) of tumor necrosis factor blocking (anti-TNF) agents (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) compared with usual care in patients with rheumatoid arthritis (RA) and low disease activity.
UR - http://www.scopus.com/inward/record.url?scp=84908392056&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD010455
DO - 10.1002/14651858.CD010455
M3 - Article
SN - 1469-493X
VL - 2013
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 4
M1 - CD010455
ER -